X

Trial Profile

Recovery From Optimal Neuromuscular Blockade in the Critically Ill: Randomized Control Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glycopyrrolate (Primary) ; Neostigmine (Primary) ; Rocuronium bromide (Primary) ; Sugammadex (Primary)
Indications Neuromuscular blockade
Focus Therapeutic Use

Most Recent Events

05 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2019).
19 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Jul 2021.
19 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com